The Mitotane market 2020 research report is a detailed view of market opportunity by end-user segments, product Type segments, sales channels, key countries. It also provides market credentials such as history, various development and trends, market overview, regional markets and also market competitors. The report estimates the performance of the key players by 2024 .
Global Mitotane Market Overview:
According to the Business industry reports the Mitotane Market is going to have a huge growth in the upcoming years by Geographical analysis, applications segmentations and End Use Industry.
Mitotane has increased in therapeutic implication due to the exploitation of adrenocytolitic activity. The antineoplastic agent has been majorly used in adjuvant therapy for the treatment of adrenocortical carcinoma, a rare but violent endocrine tumour. Over the years, endocrinologists, surgeons, and oncologists have cooperated on developing multidisciplinary methods for the infrequent endocrine tumour. Mitotane has been the only accepted drug for giving adrenocortical carcinoma; however, its efficiency in advanced stage of the disease is arguable. Even its role as an adjuvant therapy is not above doubt, despite an array of clinical backing. Mainly, its role in paediatric patient populations is still restricted in scientific literature.
The rising demands for adjuvant therapy are a main factor overdue the escalating consumption of mitotane in treating unresectable adrenocortical carcinoma (ACC). Recent studies are also estimating its potential in patients after complete surgical resection. Growing popularity of therapeutic approaches for treating Cushing’s disease, a concomitant syndrome linked with ACC, is also increasing the mitotane market. Oftentimes, ACC is analysed in later stages, a key factor behind the popularity of mitotane. Over the past few years, the need or recurrence-free existence rate in patients with ACC has also extended the probable of the market. Further, the increasing possible of mitotane as an adjuvant therapy for palliative care is also driving the development of the mitotane market.
Moderately striking pace of commercialization of drugs for ACC, notably in evolving economies such as India, has been a key factor enhancing the market. Several studies, specifically those cooperated by endocrinologists and oncologists, are undoubtedly growing the potential of the mitotane market. This will explicitly pave way for new disease strategies based on molecular targets. This has gained momentum from growing numbers of strategic agreement and partnerships. However, more studies are needed that can clarify the mechanism of action of mitotane.
Market Key Players
Mitotane Market is moderately competitive and consists of several major players. In terms of market share, some of the major players currently dominate the market. The end-users demand is driven by safety and regulatory needs and the companies operating in the market are leveraging on strategic collaborative initiatives, to offer specialized solutions, to increase their market share and increase their profitability. The companies operating in the market are also into mergers and acquisitions of start-ups that help in improving the served market portfolio on Mitotane to strengthen their product capabilities. Among the prominent players involved in the technology market, companies such as
Bristol Meyers Squibb
HRA Pharma…. more
The Mitotane market has been sub-grouped into type and application. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
Product Type Segmentation
Adrenal Cortical Carcinoma
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
Global Industry News:
Bristol Myers Squibb : APRIL 8, 2020
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combined with Limited Chemotherapy in First-Line Lung Cancer
oday announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) plus Yervoy (ipilimumab), administered concomitantly with a limited course of chemotherapy, for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. The FDA granted this application Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of August 6, 2020, in addition to granting Fast Track designation.
Additionally, the European Medicines Agency (EMA) validated a type II variation application for Opdivo plus Yervoy, combined with limited chemotherapy, for the same indication. Validation of the application confirms the submission is complete and begins the EMA’s centralized review process. This follows an announcement on March 26, 2020 that Ono Pharmaceutical Co., in partnership with Bristol Myers Squibb, submitted a supplemental application for Opdivo plus Yervoy combined with limited chemotherapy for consideration of manufacturing and marketing approval in Japan.
The applications were based on results from the Phase 3 CheckMate -9LA trial. In October 2019, the company announced the trial met its primary endpoint of superior overall survival (OS) at a pre-specified interim analysis.
“Despite treatment advances, there remains a serious unmet need for additional innovative treatment options for lung cancer patients globally,” said Sabine Maier, M.D., development lead, thoracic cancers, Bristol Myers Squibb. “The FDA’s acceptance and EMA’s validation of our applications represent important milestones for patients with lung cancer, and we look forward to working with regulatory authorities to bring the first and only dual immunotherapy plus limited chemotherapy regimen to patients as soon as possible.”
Key Points Covered
The report Mitotane market provides highlighting new business opportunities and supporting strategic and calculated decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on trends and developments and focuses on markets capacities and on the changing structure of the Mitotane. The report highlights powerful factors augmenting the demand in the global Mitotane market and even those hampering the market on a worldwide scale. The report provides key statistics on the market status of the Mitotane leading manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
Major Points in Table of Contents:
Global Mitotane Market Report 2020
1 Mitotane Product Definition
2 Global Mitotane Market Manufacturer Share and Market Overview
3 Manufacturer Mitotane Business Introduction
4 Global Mitotane Market Segmentation (Region Level)
5 Global Mitotane Market Segmentation (Product Type Level)
6 Global Mitotane Market Segmentation (Industry Level)
7 Global Mitotane Market Segmentation (Channel Level)
8 Mitotane Market Forecast 2020-2025
9 Mitotane Segmentation Product Type
10 Mitotane Segmentation Industry